# Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

> **NCT00011011** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 94 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** ALVAC(2)120(B,MN)GNP (vCP1452)

## Key facts

- **NCT ID:** NCT00011011
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00011011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00011011, "Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00011011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*